Another interesting project conducted by the Institute for Myorcardial Infarction Research can now begin: CAN-SHOCK has received a positive opinion from the ethics committee. The aim of the CAN-SHOCK registry study is to investigate the use of Cangrelor in patients with acute myocardial infarction and PCI after CPR, cardiogenic shock or mechanical or non-invasive ventilation in Germany. With the help of the collected data, evidence on the efficacy and safety of Cangrelor in these high-risk patients will be established. This is a solely retrospective study of patient data collected from medical files. The aim is to collect data from approximately 450 patients in 10-20 clinical trial sites in Germany over a period of 4-6 months.
Presentation of the second evaluation of the COVID-19 registry for Rhineland-Palatinate by Dr. Anselm K. Gitt, board of directors of Foundation Institute for Myocardial Infarction Research in and study director of the COVID-19 registry...Read more
Dr Anselm K. Gitt, board member of the IHF, reports on his current research results on the COVID-19 situation in hospitals in a video conference hosted by Torbjörn Kartes, member of the German BundestagRead more
The ethics committee approved the observational monitoring design for the CAN-SHOCK registry with no further conditions.Read more